High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicinOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study examined whether early parenteral antibiotics reshape the infant gut microbiota and how fully it recovers afterward. It compared nine infants given ampicillin and gentamicin within 48 hours of birth to nine matched untreated controls.
How was it studied?
Researchers used high throughput sequencing with 16S rRNA and rpoB specific primers plus quantitative PCR. Stool samples were profiled 4 and 8 weeks after antibiotic treatment ended.
What did they find?
At 4 weeks, treated infants had significantly higher Proteobacteria (P = 0.0049) and significantly lower Actinobacteria (P = 0.00001), Bifidobacterium (P = 0.0132) and Lactobacillus (P = 0.0182) than controls. By 8 weeks Actinobacteria, Bifidobacterium and Lactobacillus levels had recovered to control-like proportions, but Proteobacteria stayed elevated (P = 0.0049). rpoB pyrosequencing also showed fewer distinct Bifidobacterium species in treated infants despite the numeric recovery.
Why it matters
Early combined ampicillin and gentamicin exposure produces lasting shifts in gut community structure that outlast the antibiotic course. Recovery of overall bacterial abundance can mask a persistent loss of Bifidobacterium species diversity, and long-term health consequences remain unknown.